Since Pirfenidone is metabolised with the CYP1A2 enzyme pathway, any drug which inhibits this enzyme is likely to precipitate the toxicity of pirfenidone: concomitant therapy should be to be avoided. Steer clear of; coadministration of pirfenidone and moderate CYP1A2 inhibitors cause reasonably enhanced exposure to pirfenidone; if unable to keep https://crossq999hte3.blogunok.com/profile